



PO Box 77000, Nelson Mandela University, Port Elizabeth, 6031, South Africa mandela.ac.za

Chairperson: Research Ethics Committee (Human)
Tel: +27 (0)41 504 3624
Dalray.Gradidge@mandela.ac.za

NHREC registration nr: REC-042508-025

Ref: [H22-BES-BMA-164 / Extension]
Approval: [20 March 2023 – 20 March 2025]

12 March 2024

Prof S Farrington
Faculty: Business and Economic Sciences

Dear Prof Farrington

IMPLEMENTING A STUDENT ENTREPRENEURSHIP SUPPORT ASSESSMENT TOOL AT NELSON MANDELA UNIVERSITY

PRP: Prof S Farrington
PI: Mr R Ismail

The request for an extension to the above-entitled study served at the Research Ethics Committee (Human) (29 February 2024) together with a study progress report for approval. We take pleasure in informing you that the Research Ethics Committee (Human) approved the progress report and the extension of data collection for protocol [H22-BES-BMA-164] until **20 March 2025**; approval is subject to the following conditions:

1. The immediate completion and return of the attached acknowledgement form (appendix 1) to Imtiaz.Khan@mandela.ac.za.
2. The submission of an annual progress report by the PRP on the data collection activities of the study (form RECH-004 available on Research Ethics Committee (Human) portal) by 15 November this year for studies approved/extended in the period October of the previous year up to and including September of this year, or 15 November next year for studies approved/extended after September this year.
3. In the event of a requirement to extend the period of data collection, completion of an extension request is required (form RECH-005 available on Research Ethics Committee (Human) portal) and should be submitted 4-6 weeks prior to approval lapsing. In the event that an extension request is submitted after the ethics approval lapsing, a new application must be submitted via the relevant channels.
4. In the event of any changes made to the study (excluding extension of the study), RECH will have to approve such amendments and completion of an amendments form is required PRIOR to implementation (form RECH-006 available on Research Ethics Committee (Human) portal).
5. Immediate submission (and possible discontinuation of the study in the case of serious events) of an Adverse Event Report to RECH (form RECH-007 available on Research Ethics Committee (Human) portal) in the event of any unanticipated problems, serious incidents or adverse events observed during the course of the study.
6. Immediate submission of a Study Termination Report to RECH (form RECH-008 available on Research Ethics Committee (Human) portal) upon expected or unexpected closure/termination of study.
7. Immediate submission of a Study Exception Report to RECH in the event of any study deviations, violations and/or exceptions.
8. Acknowledgement that the study could be subjected to passive and/or active monitoring without prior notice at the discretion of Research Ethics Committee (Human).

Please quote the ethics clearance reference number in all correspondence and enquiries related to the study. For speedy processing of email queries (to be directed to Imtiaz.Khan@mandela.ac.za), it is recommended that the ethics clearance reference number together with an indication of the query appear in the subject line of the email.

We wish you well with the study.

Yours sincerely

A handwritten signature in black ink, appearing to read 'D Gradidge', with a long horizontal stroke extending to the right.

Dr D Gradidge
Chairperson: Research Ethics Committee (Human)

Cc: Office of Research Development
Faculty Manager: Business and Economic Sciences


Appendix 1: Acknowledgement of conditions for ethical approval

APPENDIX 1**ACKNOWLEDGEMENT OF CONDITIONS FOR ETHICS APPROVAL – EXTENSION**

I, **Prof S Farrington** (PRP) of the study entitled **IMPLEMENTING A STUDENT ENTREPRENEURSHIP SUPPORT ASSESSMENT TOOL AT NELSON MANDELA UNIVERSITY [H22-BES-BMA-164]**, do hereby agree to the following approval conditions:

1. The submission of an annual progress report by myself on the data collection activities of the study by 15 November this year for studies approved in the period October of the previous year up to and including September of this year, or 15 November next year for studies approved after September this year. It is noted that there will be no call for the submission thereof. The onus for submission of the annual report by the stipulated date rests on myself. I am aware of the guidelines (available on Research Ethics Committee (Human) portal) pertinent to the submission of the annual report.
2. Submission of the relevant request to RECH in the event of any amendments to the study for approval by RECH prior to any partial or full implementation thereof. I am aware of the guidelines (available on Research Ethics Committee (Human) portal) pertinent to the requesting for any amendments to the study.
3. Submission of the relevant request to RECH in the event of any extension to the study for approval by RECH prior to the implementation thereof.
4. Immediate submission of a report to RECH in the event of any unanticipated problems, serious incidents or adverse events. I am aware of the guidelines (available on Research Ethics Committee (Human) portal) pertinent to the reporting of any unanticipated problems, serious incidents or adverse events.
5. Immediate discontinuation of the study in the event of any serious unanticipated problems, serious incidents or serious adverse events.
6. Immediate submission of the relevant report to RECH in the event of the unexpected closure/discontinuation of the study (for example, de-registration of the PI).
7. Immediate submission of a report to RECH in the event of study deviations, violations and/or exceptions. I am aware of the guidelines (available on Research Ethics Committee (Human) portal) pertinent to the reporting of any study deviations, violations and/or exceptions.
8. Acknowledgement that the study could be subjected to passive and/or active monitoring without prior notice at the discretion of RECH. I am aware of the guidelines (available on Research Ethics Committee (Human) portal) pertinent to the active monitoring of a study.

Signed: _____


Date: 12 March 2024